Patients with INOCA in the ISCHEMIA Trial

There has been an increase in the diagnosis of patients with proven ischemia who did not present obstructive coronary lesions (defined as the absence of stenosis ≥50%), called ischemia with non-obstructive coronary arteries (INOCA). These patients are at a higher risk for major adverse cardiac events (MACE) compared with the rest of the population.

TRICVALVE en pacientes con Insuficiencia tricuspídea severa: resultados alentadores a 6 meses

The ISCHEMIA trial, one of the most relevant trials in recent years, enrolled patients with moderate to severe ischemia as evidenced in functional testing and randomized them to clinical treatment vs. angioplasty. However, 21% of enrolled patients did not present obstructive coronary disease in the baseline computed tomography angiography and, therefore, were not included in the final randomization.

The aim of this analysis of the ISCHEMIA trial was to characterize patients with INOCA in terms of clinical characteristics and ischemia degree.

The ischemia-evoking methods used were myocardial perfusion study (PET), stress echocardiogram, and magnetic resonance imaging. Ischemia severity was determined in an independent central lab (Core Lab). Patients who did not undergo computed tomography angiography or who had undergone prior myocardial reperfusion surgery or coronary angioplasty were excluded.

Read also: A Simple Score for Mortality and Cardiac Failure after Edge-to-Edge with MitraClip.

Out of the 4211 initial participants, 688 did not have coronary obstruction ≥50% detected with tomography (16.3% INOCA). Additionally, 212 patients with mild or no ischemia were excluded, so the final analyzed cohort included 476 patients. Among patients with INOCA, 27.3% had normal coronary arteries, and the rest presented some degree of stenosis.

When comparing patients with significant coronary obstruction, patients with INOCA and moderate to severe ischemia were younger (mean age: 60 vs. 63 years old; p < 0.001) and most of them were female (53.6% vs. 20.6%; p < 0.001). The highest proportion of patients with INOCA was found among those with moderate ischemic burden.

The INOCA diagnosis odds ratio between female patients compared with male patients was 4.2 (95% confidence interval: 3.4-5.2; p < 0.001). When analyzing the differences in non-obstructive disease in terms of sex, the number of segments and the involvement score were higher in male subjects (p < 0.001).

Read also: Nonobstructive Coronary Lesions and Ventricular Dysfunction.

A multivariate analysis was conducted. A diagnosis of non-obstructive disease was associated with younger, female, non-diabetic patients, with no prior AMI and lower severe ischemia index.

Conclusions

In this analysis of patients enrolled in the ISCHEMIA trial, INOCA was observed in 13% of them, meaning that, when evaluating patients with moderate to severe ischemia, it is paramount to consider ischemia-causing variables other than clear atherosclerosis, namely microvascular dysfunction, reduced flow reserve, coronary spasms, etc. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Ischemia With Non obstructive Coronary Arteries.

Font: Reynolds HR, Diaz A, Cyr DD, Shaw LJ, Mancini GBJ, Leipsic J, Budoff MJ, Min JK, Hague CJ, Berman DS, Chaitman BR, Picard MH, Hayes SW, Scherrer-Crosbie M, Kwong RY, Lopes RD, Senior R, Dwivedi SK, Miller TD, Chow BJW, de Silva R, Stone GW, Boden WE, Bangalore S, O’Brien SM, Hochman JS, Maron DJ; ISCHEMIA Research Group. Ischemia With Nonobstructive Coronary Arteries: Insights From the ISCHEMIA Trial. JACC Cardiovasc Imaging. 2022 Sep 13:S1936-878X (22)00406-5. doi: 10.1016/j.jcmg.2022.06.015. Epub ahead of print. PMID: 36115814.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...